Novel Oral Tx Dramatically Reduces Menopausal Flushing
Treatment part of new class of neurokinin 3 receptor antagonists
A neurokinin 3 receptor (NK3R) antagonist was effective at improving vasomotor symptoms without the need for estrogen exposure, both in the short and long-term, researchers reported.
The oral NK3R antagonist MLE4901 was able to reduce the frequency of hot flashes by 72% by day 3 of treatment versus baseline symptoms (95% CI -81.3% to -63.5%) and a 51% improvement in frequency with the oral treatment compared with those on placebo, according to Julia K. Prague, MBBS, of Imperial College London, and colleagues./.../
No comments:
Post a Comment